Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… ProQR Announces First Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … for the same period last year. Research and development (R&D) costs were €12.8 million for the quarter ended March 31, …
… ProQR to Participate in the Kempen Life Sciences Conference … & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Kempen Life Sciences Conference on April 20, 2022. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR to Present at the Evercore ISI HealthConX Conference … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR to Present at Two Investor Conferences in October … Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … will be held from October 2-4, 2019 in New York, NY. ProQR will present on Wednesday, October 2, 2019 at 3:35 pm …